Xlife Sciences AG Reports Strategic Growth and Technological Milestones in 2024

Xlife Sciences AG has released its 2024 Annual Report, highlighting significant strategic partnerships and technological breakthroughs. The company, listed on the SIX Swiss Exchange, strengthened its global presence by collaborating with entities like the Abu Dhabi Department of Health and Thermo Fisher Scientific. A notable merger between its portfolio companies, palleos healthcare GmbH and OCT Clinical GmbH, marked an advancement in clinical research.

Technologically, x-nuclear diagnostics GmbH reached a market-ready stage for a novel liver diagnostic procedure. inflamed pharma GmbH progressed significantly in drug solubility, showcasing the platform's capacity to enhance active pharmaceutical ingredients' solubility.

VERAXA Biotech AG introduced an innovative BiTAC platform to improve cancer therapy. Following these developments, Xlife Sciences proposes a dual listing on the Swiss and London Stock Exchanges to enhance capital market presence, targeting increased international visibility and investor access.